Videos
On today’s show I talk with Dr. Adam Back. Adam is a Bitcoin core developer, inventor of Proof of Work, and CEO/founder of Blockstream. On the show we talk about his early developments and where he’s taking Blockstream in the future.

IN THIS EPISODE, YOU’LL LEARN:
– How did Dr. Back discover Proof of Work (PoW)?
– Is Proof of Work a vital component of Bitcoin’s price floor
– Blockstreams new initiative into mining
– Blockstreams new issuance of a debt note that pays Bitcoin coupons
– Using digital tokens on liquid for registry purposes for the note
– How mining can reduce volatility while still capturing significant upside
– Dr. Back’s thoughts on the Bitcoin contango trade

Subscribe to We Study Billionaires podcast show: https://link.chtbl.com/WSB
To access our show notes, courses or forums, go to theinvestorspodcast.com.
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
ADDITIONAL INVESTING RESOURCES:
Ask the Investors: https://www.youtube.com/playlist?list=PL_xlkwLDH1F8msJn1pD3z95KuFLQWPuf-

Asset Allocation Course: https://www.youtube.com/playlist?list=PL_xlkwLDH1F9coxc1aExB8xbw9daFDF6P

Real Estate Investing: https://www.youtube.com/playlist?list=PL_xlkwLDH1F_p00VYv3psJ8rhDAGOvR5W

Millennial Investing: https://www.youtube.com/playlist?list=PL_xlkwLDH1F-NVcnR47rMkT0ByTWQBvBf
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
Download Stig & Preston’s 1-page checklist for finding great stock picks: https://www.theinvestorspodcast.com/form-youtube-checklist/

Have a question? Get your voice heard on the show: https://www.theinvestorspodcast.com/your-questions/
? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
DISCLAIMER: This show is for entertainment purposes only. Before making any decisions consult a professional. This show is copyrighted by The Investor’s Podcast Network. Written permission must be granted before syndication or rebroadcasting.

Articles You May Like

Point72’s Steve Cohen is stepping back from trading his own book
Rate Cuts to Energize Markets, Score Investors Tremendous Profits
3 More AI Stocks to “Buy the Dip”
Your favorite stocks may soon be quoted in half-penny increments – which could cut trading costs
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors